🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Vedang Murthy gaganprakash IBCG Shilpa Gupta Neeraj Agarwal, MD, FASCO Sumanta K. Pal, MD, FASCO UroToday.com DrBagrodia World Bladder Cancer Patient Coalition Jaspreet Sandhu Sewanti Limaye 🇮🇳🇺🇸 Philippe spiess Thank you! So glad you enjoyed it – it was a fantastic group and a refreshing format, though I’ll admit it was a bit nerve-racking to be grilled so intensely by the who’s who of UroOncology in Mumbai!

Just in The Lancet Oncology The PROs from the EV-302 trial, which led to the global approval of 1L EV+pembro in mUC 👉EV+P led to clinically meaningful pain relief, esp. in pts with moderate-severe baseline pain 👉EV+P led to better EORTC QLQ-C30 functioning and QoL improvements

#walkforbladdercancer Fight Bladder Cancer ActionBladderCancer World Bladder Cancer Patient Coalition #bcam IBCG

Fight Bladder Cancer ActionBladderCancer World Bladder Cancer Patient Coalition IBCG Prof Param Mariappan FRCS(Urol), PhD Lars Dyrskjøt Ashish M. Kamat, MD, MBBS Prof Ananya💙 @achoud72.bsky.social Chorley & Royal Preston BBC Lancashire

Very proud of our own Saad Atiq National Cancer Institute senior fellow presenting data on the Prevalence of Histology-Agnostic Biomarkers in Pure Squamous Cell Carcinomas of the #Bladder showing 1/3 of patients with TMB-High ASCO #ASCO25 Caris Life Sciences

#ASCO25 Was humbled to see a patient approach me on the heels of our presentation yesterday & sharing his experience of achieving CR with EV-P & maintaining it despite on a break from EV for neuropathy. He thanked us for validating his personal experience & providing reassurance

Sequential gemcitabine and docetaxel examined in BCG-unresponsive #BladderCancer patients. yair lotan UT Southwestern Urology joins Ashish M. Kamat, MD, MBBS MD Anderson Cancer Center to discuss a multicenter retrospective study comparing sequential intravesical gemcitabine and docetaxel (gem/doce) with BCG in

IBCG

Ashish M. Kamat, MD, MBBS IBCG UroToday.com Roger Li Shilpa Gupta Amanda Myers Petros Grivas Joan Palou Redorta Sima Porten Philippe spiess Very excited for this opportunity to support our rising stars and get them involved in our global initiatives!

Excellent opportunity Ashish M. Kamat, MD, MBBS IBCG

Great pleasure during #AUA25 to discuss with Joshua Meeks and Ashish M. Kamat, MD, MBBS the futur of BCG naive field The tremendous IBCG plenary session was fantastic, really enjoyed our debate leaded by Laura S. Mertens urotoday.com/video-lectures…

FDA approves UGN-102, mitomycin intravesical solution (ZUSDURI™ ) for Recurrent Low-Grade IR NMIBC businesswire.com/news/home/2025… UroGen Pharma Roger Li Sia Daneshmand, M.D. Max Kates IBCG Joan Palou Redorta

We'd like to thank all the collaborators involved in making this study a reality Sia Daneshmand, M.D. Sam S. Chang MD, MBA Ashish M. Kamat, MD, MBBS Vignesh Packiam, MD Yair Lotan Patrick Hensley, MD Vikram M. Narayan, MD Stephen B. Williams, MD, MBA, MS, FACHE Roger Li Philippe spiess, John Taylor, Mike O'Donnell, Mario I Fernandez, Bryn M. Launer, MD

We are pleased to share our new publication in European Urology validating Vesta Risk Stratify biomarkers for prediction of recurrence and progression in High Grade Ta Bladder Cancer. Press Release: businesswire.com/news/home/2025… Grateful to all the collaborators involved and

Uromigos Ashish M. Kamat, MD, MBBS Tom Powles Sam S. Chang MD, MBA Mark Tyson Stephen Boorjian, MD DrBagrodia Stacy Loeb, MD Alexander Kutikov MD Angie Smith Trying to keep up with the Uromigos on this whirlwind tour through the rapidly evolving landscape of therapies in NMIBC. Ashish M. Kamat, MD, MBBS Sia Daneshmand, M.D. Petros Grivas Laura Bukavina Andrea Necchi Matt Galsky Benjamin Pradere IBCG Mark Tyson Max Kates Sam S. Chang MD, MBA

Nicely done Joshua Meeks Uromigos IBCG

Joshua Meeks Uromigos Ashish M. Kamat, MD, MBBS Tom Powles Sam S. Chang MD, MBA Mark Tyson Stephen Boorjian, MD DrBagrodia Stacy Loeb, MD Alexander Kutikov MD Angie Smith Sia Daneshmand, M.D. Petros Grivas Laura Bukavina Andrea Necchi Matt Galsky Benjamin Pradere IBCG Max Kates Hey Josh, pointing out the misprint: Reinduction was NOT allowed in the nadofaragene firadenovec trial.

Daniel Shoskes MD, FRCS(C) Uromigos Ashish M. Kamat, MD, MBBS Tom Powles Sam S. Chang MD, MBA Mark Tyson Stephen Boorjian, MD DrBagrodia Stacy Loeb, MD Alexander Kutikov MD Angie Smith Sia Daneshmand, M.D. Petros Grivas Laura Bukavina Andrea Necchi Matt Galsky Benjamin Pradere IBCG Max Kates Thank you for catching my error, Daniel Shoskes MD, FRCS(C). Agree that an important part of interpreting "CR" is induction vs induction and re-induction. Below is the revised table.

Our stratification for primary IR-NMIBC aligns with the IBCG model—same risk factors, further validation. FU should be based on size & focality. Suggested schedule: 🔸 IR-High: cysto q3–4mo (Y1), then q6mo to Y3 → IR-Low 🔹 IR-Low: standard EAU protocol.